Diminished airway host innate response in people with cystic fibrosis who experience frequent pulmonary exacerbations.


Journal

The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460

Informations de publication

Date de publication:
22 Dec 2023
Historique:
received: 20 07 2023
accepted: 06 12 2023
medline: 23 12 2023
pubmed: 23 12 2023
entrez: 22 12 2023
Statut: aheadofprint

Résumé

Pulmonary exacerbations (PEx) are clinically impactful events that accelerate cystic fibrosis (CF) lung disease progression. The pathophysiological mechanisms underlying an increased frequency of PEx have not been explored. To compare host immune response during intravenous antibiotic treatment of PEx in people with CF who have a history of frequent Adults with CF were recruited at onset of antibiotic treatment of a PEx and were categorized as infrequent or frequent exacerbators based on their PEx frequency in the previous 12 months. Clinical parameters, sputum bacterial load and sputum inflammatory markers were measured on day 0, day 5 and at the end of treatment. Shotgun proteomic analysis was performed on sputum using liquid chromatography-mass spectrometry. Many sputum proteins were differentially enriched between infrequent and frequent exacerbators (day 0=23 and day 5=31). The majority of these proteins had a higher abundance in infrequent exacerbators and were secreted innate host defence proteins with antimicrobial, antiprotease and immunomodulatory functions. Several differentially enriched proteins were validated by ELISA and Western blot including SLPI, lipocalin-1 and cystatin SA. Sputum from frequent exacerbators demonstrated potent ability to cleave exogenous recombinant SLPI in an NE-dependent manner. Frequent exacerbators had increased sputum inflammatory markers (IL-1β and IL-8) and total bacterial load compared to infrequent exacerbators. A diminished innate host protein defence may play a role in the pathophysiological mechanisms of frequent CF PEx. Frequent exacerbators may benefit from therapies targeting this dysregulated host immune response.

Identifiants

pubmed: 38135443
pii: 13993003.01228-2023
doi: 10.1183/13993003.01228-2023
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright ©The authors 2023.

Auteurs

Claire J Houston (CJ)

Airway Innate Immunity Research Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, , Northern Ireland, UK.

Aya Alkhatib (A)

School of Pharmacy, Queen's University Belfast, Northern Ireland, UK.

Gísli G Einarsson (GG)

School of Pharmacy, Queen's University Belfast, Northern Ireland, UK.

Michael M Tunney (MM)

School of Pharmacy, Queen's University Belfast, Northern Ireland, UK.

Clifford C Taggart (CC)

Airway Innate Immunity Research Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, , Northern Ireland, UK.
joint senior authors.

Damian G Downey (DG)

Belfast Health and Social Care Trust, Northern Ireland, UK d.downey@qub.ac.uk.
Wellcome-Wolfson Institute for Experimental Medicine, BT9 7BL, Queen's University Belfast, Northern Ireland, UK.
joint senior authors.

Classifications MeSH